Profiling the immune stromal interface in breast cancer and its potential for clinical impact

Breast Care

Volumn 7, Issue 4, 2012, Pages 273-280

  Irshad, Sheeba ^a   Grigoriadis, Anita ^a   Lawler, Katherine ^b   Ng, Tony ^b   Tutt, Andrew ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Breast cancer; Genomic biomarkers; Immune stromal interface

Indexed keywords

ANTHRACYCLINE; ANTIVIRUS AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ESTROGEN RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; INTERFERON; INTERLEUKIN 8; MESSENGER RNA; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; STAT1 PROTEIN; TOLL LIKE RECEPTOR 4; VASCULOTROPIN;

ADJUVANT THERAPY; ANTIVIRAL ACTIVITY; B LYMPHOCYTE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION PROFILING; GENOMIC INSTABILITY; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; LYMPHOCYTIC INFILTRATION; MICRODISSECTION; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE FRACTIONATION; REVIEW; TRIPLE NEGATIVE BREAST CANCER; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84866951171     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000341529     Document Type: Review

References (64)

1. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, Funke R, et al.: Initial sequencing and analysis of the human genome. Nature 2001;409:860-921.
2. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, Yandell M, Evans CA, Holt RA, Gocayne JD, et al.: The sequence of the human genome. Science 2001;291:1304-1351.
3. Campa D, Kaaks R, Le Marchand L, Haiman CA, Travis RC, Berg CD, Buring JE, Chanock SJ, Diver WR, Dostal L, Fournier A, et al.: Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium. J Natl Cancer Inst 2011;103:1252-1263.
4. Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, Bojesen SE, Nordestgaard BG, Axelsson CK, Arias JI, Milne RL, et al.: Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 2008;4:e1000054.
5. Peng R, Wang S, Shi Y, Liu D, Teng X, Qin T, Zeng Y, Yuan Z: Patients 35 years old or younger with operable breast cancer are more at risk for relapse and survival: a retrospective matched casecontrol study. Breast 2011;20:568-573.
6. Kwei KA, Kung Y, Salari K, Holcomb IN, Pollack JR: Genomic instability in breast cancer: pathogenesis and clinical implications. Mol Oncol 2010;4:255-266.
7. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, Stebbings LA, Leroy C, Edkins S, Mudie LJ, Greenman CD, et al.: Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009;462:1005-1010.
8. Iorio MV, Croce CM: MicroRNA involvement in human cancer. Carcinogenesis 2012;Epub ahead of print.
9. Nambiar PR, Gupta RR, Misra V: An 'omics' based survey of human colon cancer. Mutat Res 2010;693:3-18.
10. Tran B, Dancey JE, Kamel-Reid S, McPherson JD, Bedard PL, Brown AM, Zhang T, Shaw P, Onetto N, Stein L, Hudson TJ, et al.: Cancer genomics: technology, discovery, and translation. J Clin Oncol 2012;30:647-660.
11. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, et al.: Molecular portraits of human breast tumours. Nature 2000;406:747-752.
12. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM: Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010;12:R68.
13. Sotiriou C, Pusztai L: Gene-expression signatures in breast cancer. N Engl J Med 2009;360:790-800.
14. Weigelt B, Mackay A, A'Hern R, Natrajan R, Tan DS, Dowsett M, Ashworth A, Reis-Filho JS: Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol 2010;11:339-349.
15. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, et al.: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012;486:346-352.
16. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, et al.: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-892.
17. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, Bashashati A, et al.: The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012;486:395-399.
18. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-998.
19. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD: Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007;450:903-907.
20. Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature 2008;454: 436-444.
21. Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA, Fearon DT: Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010;330:827-830.
22. Teng MW, Swann JB, Koebel CM, Schreiber RD, Smyth MJ: Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol 2008;84:988- 993.
23. Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, Horng CF, Bild A, Iversen ES, Liao M, Chen CM, West M, et al.: Gene expression predictors of breast cancer outcomes. Lancet 2003;361:1590-1596.
24. Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, Pergamenschikov A, Williams CF, Zhu SX, Lee JC, Lashkari D, et al.: Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A 1999;96:9212-9217.
25. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, Hallett M, et al.: Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008;14:518-527.
26. Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, Engels K, et al.: T-cell metagene predicts a favorable prognosis in estrogen receptor- negative and HER2-positive breast cancers. Breast Cancer Res 2009;11:R15.
27. Hsu SD, Anders CK, Acharya CR, Zhang Y, Wang Y, Foekens JA, Blackwell KL, Drake CG, Morse MA, Febbo PG: Immune signatures hold prognostic import across solids tumors. J Clin Oncol 2007;25:21041.
28. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H, Lehr HA, Hengstler JG, Kolbl H, Gehrmann M: The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 2008;68:5405-5413.
29. Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, et al.: Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. J Clin Oncol 2010;28:4316-4323.
30. Alexe G, Dalgin GS, Scanfeld D, Tamayo P, Mesirov JP, DeLisi C, Harris L, Barnard N, Martel M, Levine AJ, Ganesan S, et al.: High expression of lymphocyte-associated genes in nodenegative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res 2007;67:10669- 10676.
31. Kandalaft LE, Coukos G: The microenvironment of ovarian cancer: lessons on immune mediated tumor rejection or tolerance; in Wang E, Marincola FM (eds): Signatures of Rejection, 1st ed.Springer, New York, NY, 2010.
32. Adams SF, Levine DA, Cadungog MG, Hammond R, Facciabene A, Olvera N, Rubin SC, Boyd J, Gimotty PA, Coukos G: Intraepithelial t cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer 2009;115:2891-2902.
33. Belgen H, Einhorn N, Sjovall K, Roschkes A, Ghadimis BM, McShane LM, Nilsson B, Shah K, Ried T, Auer G: Prognostic significance of cell cycle proteins and genomic instability in borderline, early and advanced stage ovarian carcinomas. Int J Gynecol Cancer 2000;10:477-487.
34. Duesberg P, Stindl R, Hehlmann R: Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalyzed by aneuploidy. Proc Natl Acad Sci U S A 2000;97:14295-14300.
35. McAlpine JN, Porter H, Kobel M, Nelson BH, Prentice LM, Kalloger SE, Senz J, Milne K, Ding J, Shah SP, Huntsman DG, et al.: BRCA1 and BRCA2 mutations correlate with tp53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod Pathol 2012;25:740-750.
36. Shah CA, Allison KH, Garcia RL, Gray HJ, Goff BA, Swisher EM: Intratumoral t cells, tumorassociated macrophages, and regulatory t cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. Gynecol Oncol 2008;109:215-219.
37. Yau C, Esserman L, Moore DH, Waldman F, Sninsky J, Benz CC: A multigene predictor of metastatic outcome in early stage hormone receptor- negative and triple-negative breast cancer. Breast Cancer Res 2010;12:R85.
38. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA: Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449:557-563.
39. Beresford MJ, Wilson GD, Makris A: Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res 2006;8:216.
40. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe- Kains B, Desmedt C, et al.: Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;98:262-272.
41. Van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-536.
42. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, et al.: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365:671-679.
43. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, et al.: The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006;7:96.
44. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C: An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2007;8:R157.
45. Sabatier R, Finetti P, Cervera N, Lambaudie E, Esterni B, Mamessier E, Tallet A, Chabannon C, Extra JM, Jacquemier J, Viens P, et al.: A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res Treat 2011;126:407-420.
46. Sabatier R, Finetti P, Mamessier E, Raynaud S, Cervera N, Lambaudie E, Jacquemier J, Viens P, Birnbaum D, Bertucci F: Kinome expression profiling and prognosis of basal breast cancers. Mol Cancer 2011;10:86.
47. Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L, Gaetje R, Solbach C, Ahr A, Metzler D, Schmidt M, et al.: A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res 2011;13:R97.
48. Ascierto ML, Kmieciak M, Idowu MO, Manjili R, Zhao Y, Grimes M, Dumur C, Wang E, Ramakrishnan V, Wang XY, Bear HD, et al.: A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat 2012;131:871-880.
49. Cronin M, Sangli C, Liu ML, Pho M, Dutta D, Nguyen A, Jeong J, Wu J, Langone KC, Watson D: Analytical validation of the oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem 2007;53:1084-1091.
50. Knauer M, Mook S, Rutgers EJ, Bender RA, Hauptmann M, van de Vijver MJ, Koornstra RH, Bueno-de-Mesquita JM, Linn SC, van 't Veer LJ: The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2010;120:655-661.
51. Gianni L, Baselga J, Eiermann W, Guillem Porta V, Semiglazov V, Lluch A, Zambetti M, Sabadell D, Raab G, Llombart Cussac A, Bozhok A, et al.: Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 2005;11:8715-8721.
52. Tsai MH, Cook JA, Chandramouli GV, DeGraff W, Yan H, Zhao S, Coleman CN, Mitchell JB, Chuang EY: Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. Cancer Res 2007;67:3845- 3852.
53. Ma Y, Aymeric L, Locher C, Mattarollo SR, Delahaye NF, Pereira P, Boucontet L, Apetoh L, Ghiringhelli F, Casares N, Lasarte JJ, et al.: Contribution of IL-17-producing gamma delta t cells to the efficacy of anticancer chemotherapy. J Exp Med 2011;208:491-503.
54. West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH: Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res 2011;13:R126.
55. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, von Torne C, et al.: Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010;28:105-113.
56. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, et al.: Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13:1050-1059.
57. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, Perfettini JL, et al.: Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009;15:1170-1178.
58. Ignatiadis M, Singhal SK, Desmedt C, Haibe- Kains B, Criscitiello C, Andre F, Loi S, Piccart M, Michiels S, Sotiriou C: Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol 2012;30:1996-2004.
59. Van der Burg SH, Kalos M, Gouttefangeas C, Janetzki S, Ottensmeier C, Welters MJ, Romero P, Britten CM, Hoos A: Harmonization of immune biomarker assays for clinical studies. Sci Transl Med 2011;3:108ps144.
60. O'Shea JJ, Paul WE: Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science 2010;327:1098-1102.
61. Emamian ES, Leon JM, Lessard CJ, Grandits M, Baechler EC, Gaffney PM, Segal B, Rhodus NL, Moser KL: Peripheral blood gene expression profiling in Sjogren's syndrome. Genes Immun 2009;10:285-296.
62. Julia A, Erra A, Palacio C, Tomas C, Sans X, Barcelo P, Marsal S: An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis. PLoS One 2009;4:e7556.
63. McKinney EF, Lyons PA, Carr EJ, Hollis JL, Jayne DR, Willcocks LC, Koukoulaki M, Brazma A, Jovanovic V, Kemeny DM, Pollard AJ, et al.: A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat Med 2010;16:586-591, p. 581 following p. 591.
64. Baine MJ, Chakraborty S, Smith LM, Mallya K, Sasson AR, Brand RE, Batra SK: Transcriptional profiling of peripheral blood mononuclear cells in pancreatic cancer patients identifies novel genes with potential diagnostic utility. PLoS One 2011;6:e17014.